Eric Lawatsch, MD
Urology · Neenah, WINPI 1033296520
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (44.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Intuitive Surgical at 46.5% of the total. Reporting peaked in 2023 at $3,541 and has fallen 54.6% since, to $1,606 in 2025.
Across 106 payments — averaging $63.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Procept Biorobotics Corporation$1K
- Johnson & Johnson$404
- Dendreon Pharmaceuticals LLC$384
- Pfizer$225
- Urogen Pharma, Inc.$206
- plus $1K from 24 others
Across 15 payments — averaging $7171.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$108K
What the payments were for
- Travel & lodging$91013%
- Food & beverage$2,84542%
- Education$3,01545%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 3 | $3,147 |
| Procept Biorobotics Corporation | 3 | $1,178 |
| Johnson & Johnson | 11 | $404 |
| Dendreon Pharmaceuticals LLC | 15 | $384 |
| Pfizer | 11 | $225 |
| Urogen Pharma, Inc. | 4 | $206 |
| Sumitomo Pharma America, Inc. | 6 | $197 |
| AbbVie(2 entities) | 9 | $155 |
| Myovant Sciences Inc. | 2 | $91 |
| Merck | 4 | $79 |
| Astellas Pharma US Inc | 4 | $68 |
| Bayer | 4 | $63 |
| Coloplast | 4 | $56 |
| Boston Scientific | 2 | $56 |
| Sun Pharmaceutical Industries Inc. | 2 | $46 |
| Ferring Pharmaceuticals Inc. | 2 | $42 |
| Amgen | 2 | $36 |
| Endo Pharmaceuticals Inc. | 2 | $36 |
| Novartis | 2 | $35 |
| Teleflex LLC | 2 | $34 |
| Olympus America Inc. | 2 | $33 |
| Blue Earth Diagnostics | 2 | $32 |
| Neotract Inc. | 1 | $25 |
| Tolmar Pharmaceuticals, Inc. | 1 | $24 |
| Tempus AI, Inc | 1 | $24 |
| Palette Life Sciences, Inc. | 1 | $24 |
| AstraZeneca | 1 | $19 |
| Smith+Nephew | 1 | $17 |
| Medtronic | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$3,000
- AquaBeam Robotic System$1,089
- Erleada$255
- JELMYTO$136
- Da Vinci Surgical System$134
- PROVENGE$132
How this compares
$6,770 in reported general payments places this provider in the 85th percentile of 215 urology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 66 | $867,167 |
| ErleadaApalutamide | 51 | $713,837 |
| XtandiEnzalutamide | 40 | $543,974 |
| OrgovyxRelugolix | 65 | $179,930 |
| Abiraterone Acetate | 68 | $129,825 |
| MyrbetriqMirabegron | 57 | $36,764 |
| Tamsulosin Hcl | 590 | $10,585 |
| GemtesaVibegron | 12 | $10,449 |
| Potassium Citrate ErPotassium Citrate | 26 | $6,263 |
| Finasteride | 234 | $3,103 |
| Solifenacin Succinate | 66 | $2,281 |
| Methenamine Hippurate | 29 | $1,884 |
| Desmopressin Acetate | 18 | $1,341 |
| Tolterodine Tartrate ErTolterodine Tartrate | 16 | $1,293 |
| Megestrol Acetate | 20 | $992 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $63 | $867,16766 claims |
| Johnson & JohnsonErleada | $404 | $713,83751 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $68 | $580,73897 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $197 | $190,37977 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 215 urology providers in Wisconsin.
Other urology in Neenah
- Kevin FlynnNeenah$56K
- Erin SalterNeenah$6K
- Dan GralnekMadison$142K
- Amy GuiseMilwaukee$106K
- Christopher ManakasMadison$87K
- Bahareh Alavi-DunnGreen Bay$62K
- Javier SantiagoMadison$57K
- Margaret KnoedlerMadison$31K
- Jeremy ReesePleasant Prairie$27K
- Edwin AbelMadison$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.